№ lp_1_20402
File format: docx
Character count: 5941
File size: 3522 KB
Supplemental guide detailing updates to infusion therapy plans for ambulatory clinicians at Duke Health, introducing silo-based management for improved coordination of multiple treatment plans.
Note:
Year
Topic:
Infusion Therapy Plans
Document Type:
Internal Update
Organization:
Duke Health
Target Audience:
Ambulatory Clinicians
Specialties:
Hematology, Solid Organ Transplant, Oncology, Pediatrics
Related Locations:
Duke Specialty Infusion, South Durham Infusion, Oncology Treatment Center, DUH Macon Pond Infusion, DUH Cary Infusion, DRAH Infusion Clinic
Therapy Plans:
Apheresis, Oncology/ABMT, Transplant, Peds/PBMT, Iron Products
Therapy Plan Features:
Silo-based Therapy Management, Multi-Specialty Integration
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Organization:
Canberra Health Services
Department:
Neonatology
Document Type:
Procedure
Target Audience:
Medical Officers, Registered Nurses, Midwives, Student Nurses under supervision
Scope:
Neonates from birth to 44 weeks corrected gestational age
Related Policies:
Neonatal Intensive Care Drug Manual, ANMF guidelines
Definitions Included:
Blood Glucose Levels, Hyperglycaemia, Significant Hyperglycaemia
Treatment Recommendations:
Insulin infusion, glucose monitoring, TPN and enteral feeding guidance
Risks Addressed:
Hypoglycaemia, glucose delivery variability, insulin-plastic binding
Year:
2026
Region / City:
European Union
Subject:
Pharmaceutical Product Information
Document Type:
Pharmaceutical Summary
Organization:
European Medicines Agency
Author:
European Medicines Agency
Target Audience:
Healthcare professionals
Period of validity:
Ongoing
Approval Date:
2026
Date of Modifications:
2026
Contextual Description:
The document outlines the product characteristics, indications, dosage, administration guidelines, and precautions for the pharmaceutical product Tysabri, as approved by the European Medicines Agency.
Year:
2025
Region / City:
Australia
Topic:
Pharmaceutical submission for drug listing
Document Type:
Pharmaceutical submission
Organization:
Janssen-Cilag Pty Ltd
Author:
Not specified
Target Audience:
Healthcare professionals, regulatory authorities
Validity Period:
Not specified
Approval Date:
Not specified
Date of Changes:
March 2025
Note:
Context
Year:
2022
Region / City:
Australia
Topic:
Medical treatment approval and submission for pembrolizumab and lenvatinib
Document type:
Submission for drug listing
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC), Therapeutic Goods Administration (TGA)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Medical professionals, health regulators
Period of validity:
2022 onward
Approval date:
August 10, 2021
Amendment date:
Not specified
Year:
2023
Region / City:
Australia
Theme:
Oncology, Pharmaceutical
Document Type:
Submission
Organization / Institution:
Merck Sharp & Dohme (Australia) Pty Ltd
Author:
Not specified
Target Audience:
Medical professionals, policymakers
Period of Effectiveness:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2018
Region / City:
Australia
Topic:
Pharmaceutical Submission, Cancer Treatment
Document Type:
Submission
Organization / Institution:
Takeda Pharmaceuticals Australia Pty Ltd
Author:
Takeda Pharmaceuticals Australia Pty Ltd
Target Audience:
Healthcare professionals, PBAC
Period of Validity:
Ongoing
Approval Date:
23 May 2018
Date of Amendments:
Not specified
Year:
2023
Region / City:
Australia
Subject:
Oncology / Colorectal Cancer Treatment
Document Type:
Medical submission
Agency / Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Not specified
Target Audience:
Medical practitioners
Effective Period:
Ongoing
Approval Date:
Not provided
Date of Revision:
Not provided
Year:
2023
Region / city:
N/A
Topic:
Smart infusion pumps, medication infusion, safety
Document type:
Draft Safe Practice Statements
Organization / institution:
Institute for Safe Medication Practices (ISMP)
Author:
N/A
Target audience:
Healthcare providers, clinicians, medical staff
Period of validity:
N/A
Date of approval:
N/A
Date of modifications:
N/A
Context:
This document outlines safe practices for the implementation and use of smart infusion pumps in healthcare settings, with a focus on medication safety and infusion protocols.
Note:
Year
Topic:
Home Health Services, Durable Medical Equipment, Home Infusion Services, Authorization
Document Type:
Authorization Process Description
Organization / Institution:
CareCentrix, BlueCard
Target Audience:
Healthcare Providers, BlueCard Providers
Year:
2022
Region / City:
ACT and surrounding NSW
Topic:
Paediatric Diabetes Care, Insulin Pump Therapy
Document Type:
Clinical Guideline
Organization:
Canberra Health Services (CHS)
Author:
Canberra Health Services, Paediatric Endocrinology and Diabetes Service
Target Audience:
Paediatric Diabetes Healthcare Providers
Period of Validity:
N/A
Approval Date:
N/A
Date of Last Revision:
N/A
Year:
2026
Region / city:
Canberra
Topic:
Insulin infusion management in hospital settings
Document type:
Procedure
Organization / institution:
Canberra Health Services
Author:
Not specified
Target audience:
Medical officers, nurses, midwives, ICU/HDU/ED staff at North Canberra Hospital
Effective period:
Not specified
Approval date:
Not specified
Revision date:
Not specified
Year:
2024
Region / City:
Australia
Topic:
Oncology / Cancer Treatment
Document Type:
Pharmaceutical Submission
Organization:
Merck Sharp & Dohme
Author:
Merck Sharp & Dohme
Target Audience:
Healthcare professionals, regulatory bodies, pharmaceutical industry
Effective Period:
From September 2024
Approval Date:
Pending
Date of Changes:
September 2024
Context:
A submission by Merck Sharp & Dohme to request a multi-indication listing for pembrolizumab to treat advanced or metastatic cancers under the Pharmaceutical Benefits Scheme in Australia.
Year:
2024
Region / city:
Australia
Topic:
Thyroid eye disease (TED), Medical treatment, Drug submission
Document type:
Submission for drug listing approval
Organization:
PBAC, TGA
Author:
AMGEN AUSTRALIA PTY LTD
Target audience:
Medical practitioners, regulatory bodies
Period of validity:
Ongoing
Approval date:
Not yet decided
Amendment date:
December 2024
Clinical criteria:
Active, moderate-to-severe thyroid eye disease, CAS ≥ 3, specific treatment criteria
Indication:
Active, moderate-to-severe thyroid eye disease
Prescriber type:
Medical practitioners
Treatment phase:
Initial, Continuing
Category / Program:
Section 100, Authority Required (Streamlined)
Product:
Teprotumumab (Tepezza)
Comparator:
IV methylprednisolone, tocilizumab
Clinical claim:
Superior efficacy, non-inferior safety to standard treatments
Outcome measures:
Proptosis, diplopia, quality of life, adverse events
Background:
Teprotumumab undergoing TGA review, with specific recommendations from the Advisory Committee on Medicines
Year:
2023
Region / city:
Europe
Topic:
Neurology, Immunology
Document type:
Product Information
Author:
European Medicines Agency
Target audience:
Healthcare professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2024
Region / city:
Australia
Subject:
Urothelial cancer treatment
Document type:
Submission
Organization / institution:
TGA, PBAC
Author:
Not specified
Target audience:
Medical professionals
Period of validity:
2024–2026
Approval date:
Not specified
Date of changes:
Not specified
Year:
2023
Region / Country:
United States
Topic:
Law enforcement training and officer wellness
Document type:
Survey supporting statement
Agency / Institution:
Bureau of Justice Statistics (BJS)
Author:
Bureau of Justice Statistics
Target audience:
Law enforcement agencies, policymakers, researchers
Survey period:
September 2023 – May 2024
Legal authority:
34 USC § 10132
Data collection agent:
RTI International
Sample size:
Approximately 3,500 general-purpose law enforcement agencies
Related programs:
Law Enforcement Core Statistics (LECS), LEMAS core survey, Census of Law Enforcement Training Academies (CLETA), Law Enforcement Suicide Data Collection (LESDC)
Year:
2011
Region / city:
Not specified
Subject:
Manure Management
Document type:
Checklist
Agency / institution:
Not specified
Author:
Not specified
Target audience:
Farmers
Period of validity:
Not specified
Approval date:
October 29, 2011
Date of changes:
Not specified
Note:
Context description
Note:
Year
Organization / Institution:
Bishop Grosseteste University
Target Audience:
Applicants requesting a duplicate academic transcript or diploma supplement
Note:
Year
Context:
Form used to supplement the application for using live vertebrate animals in research or educational programs by providing additional personnel details and responsibilities.
Year:
2024
Region / City:
N/A
Theme:
Fantasy, Role-playing
Document Type:
Supplement
Author:
Shubu Sibbly
Target Audience:
Dungeons and Dragons players and game masters
Period of validity:
N/A
Approval Date:
N/A
Date of changes:
N/A
Contextual Description:
A supplement for Dungeons and Dragons detailing the integration of the Wolly species, including their history, design, and gameplay guidance in 5e.